MedTrace Logo

Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant

NCT02300571 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-09-05

No results posted yet for this study

Summary

This observational study is proposed to observe the effect of high-dose, post-transplantation cyclophosphamide after a T cell-replete, HLA-matched PBSC graft from an HLA-identical or mismatched donor.

Conditions

Sponsors & Collaborators

  • Fondazione del Piemonte per l'Oncologia

    lead OTHER

Principal Investigators

  • Massimo Aglietta, MD · Fondazione del Piemonte per l'Oncologia

  • Franca Fagioli, MD · Ospedale Regina Margherita

  • Fabrizio Carnevale-Schianca, MD · Fondazione del Piemonte per l'Oncologia

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300571 on ClinicalTrials.gov